We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
OctoPlus Signs Service Contract with Galapagos
News

OctoPlus Signs Service Contract with Galapagos

OctoPlus Signs Service Contract with Galapagos
News

OctoPlus Signs Service Contract with Galapagos

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "OctoPlus Signs Service Contract with Galapagos"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

OctoPlus N.V. has announced that it has signed a pharmaceutical development contract with a new client, Galapagos N.V. The undisclosed contract value significantly contributes to OctoPlus' annual revenues.

Under the contract terms, OctoPlus will manufacture clinical trial material for Galapagos' Phase II study of Nanocort®, a liposome formulation of prednisolone. OctoPlus has progressed the scale-up of the production process of this complex liposomal product.

OctoPlus provides formulation development and clinical material manufacturing services to biotech and pharmaceutical companies worldwide. In addition to its expertise in formulation and manufacturing, OctoPlus offers its clients drug delivery technologies for the development of controlled release versions of existing or new drugs.
Advertisement